What is the therapeutic effect of irinotecan hydrochloride liposome injection (Onivyde)?

Irinotecan hydrochloride liposome injection (Onivyde) has shown significant results in the treatment of metastatic pancreatic cancer, and studies have shown that its combination with other chemotherapy drugs can effectively improve patient survival rates.

A pivotal study of 770 previously untreated adult patients with pancreatic metastatic adenocarcinoma showed that patients who received irinotecan hydrochloride liposome injection in combination with oxaliplatin, 5-fluorouracil, and aldehyde folate had an average survival time of 11.1 months. This data is significantly better than that of patients who received the standard treatment of gemcitabine and nabpaclitaxel, which had an average survival time of only 9.2 months. The results of this study show that irinotecan hydrochloride liposome injection plays an important role in improving patient survival.

Another major study focused on 417 patients with metastatic pancreatic adenocarcinoma whose disease progressed after receiving gemcitabine. This study shows that the average survival time of patients who were treated with irinotecan hydrochloride liposome injection combined with fluorouracil and leucovorin was about 6.1 months, while the average survival time of patients who only received the combination of fluorouracil and leucovorin was 4.2 months. At the same time, the average survival time of patients who only used irinotecan hydrochloride liposome injection was 4.9 months. These data suggest that irinotecan hydrochloride liposome injection can provide patients with an additional chance of survival even when previous treatments have failed.

In summary, irinotecan hydrochloride liposome injection has shown good therapeutic effects in the treatment of metastatic pancreatic cancer, especially when used in combination with other chemotherapy drugs, it can significantly extend the survival time of patients and improve their quality of life. This makes it an important treatment option, especially for patients who have experienced failure of other treatment options. In clinical practice, rational application of irinotecan hydrochloride liposome injection will help improve the prognosis of patients with metastatic pancreatic cancer.

References:https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal